{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T13:03:54Z","timestamp":1754399034945,"version":"3.40.5"},"reference-count":60,"publisher":"Informa UK Limited","issue":"6","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["HIV Research & Clinical Practice"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1080\/25787489.2020.1844520","type":"journal-article","created":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T03:04:31Z","timestamp":1612321471000},"page":"151-167","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide (D\/C\/F\/TAF) single-tablet regimen in antiretroviral treatment (ART)-na\u00efve and -experienced, virologically-suppressed adults living with HIV-1"],"prefix":"10.1080","volume":"21","author":[{"given":"Gregory D.","family":"Huhn","sequence":"first","affiliation":[{"name":"Ruth M. Rothstein CORE Center, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimee","family":"Wilkin","sequence":"additional","affiliation":[{"name":"Section on Infectious Diseases, Wake Forest School of Medicine, Winston-Salem, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Mussini","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3875-5367","authenticated-orcid":false,"given":"Christoph D.","family":"Spinner","sequence":"additional","affiliation":[{"name":"School of Medicine, Technical University of Munich, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Jezorwski","sequence":"additional","affiliation":[{"name":"Janssen Research and Development LLC, Pennington, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsine","family":"El Ghazi","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV, Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Van Landuyt","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV, Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erkki","family":"Lathouwers","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV, Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberley","family":"Brown","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV, Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Baugh","sequence":"additional","affiliation":[{"name":"Janssen Research and Development LLC, Raritan, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the AMBER and EMERALD study groups","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,2,2]]},"reference":[{"key":"e_1_3_8_2_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152611795589663"},{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S31385"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001677"},{"key":"e_1_3_8_5_1","unstructured":"SYMTUZA \u00ae (darunavir cobicistat emtricitabine and tenofovir alafenamide) tablets Summary of Product Characteristics. Janssen-Cilag International NV. https:\/\/www.medicines.org.uk\/emc\/product\/8430. Published 2017. Revised July 2019. Accessed October 19 2020."},{"key":"e_1_3_8_6_1","unstructured":"Prescribing information for SYMTUZA \u00ae (darunavir cobicistat emtricitabine and tenofovir alafenamide) tablets. Janssen Pharmaceutical Companies. http:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/SYMTUZA-pi.pdf. Published 2018. Revised March 2020. Accessed October 19 2020."},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2012.01060.x"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328345ee95"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000308"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/15284336.2017.1387690"},{"key":"e_1_3_8_11_1","unstructured":"EACS. European AIDS Clinical Society Guidelines Version 10.1. https:\/\/www.eacsociety.org\/files\/guidelines-10.1.finalsept2020.pdf. Published October 2020. Accessed October 19 2020."},{"key":"e_1_3_8_12_1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services. https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/AdultandAdolescentGL.pdf. Published December 18 2019. Accessed October 19 2020."},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17025"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001817"},{"key":"e_1_3_8_15_1","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S2352-3018(17)30179-0","article-title":"Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine\/tenofovir disoproxil fumarate regimens to the once-daily complete HIV-1 regimen of darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide (D\/C\/F\/TAF) in virologically suppressed, HIV-1-infected adults through 48 weeks (EMERALD): a phase 3, randomised, non-inferiority trial","volume":"5","author":"Orkin C","year":"2018","unstructured":"Orkin C, Molina J-M, Negredo E, et\u00a0al. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine\/tenofovir disoproxil fumarate regimens to the once-daily complete HIV-1 regimen of darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide (D\/C\/F\/TAF) in virologically suppressed, HIV-1-infected adults through 48 weeks (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV 2018;5:e23\u2013e34.","journal-title":"Lancet HIV"},{"key":"e_1_3_8_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002463"},{"key":"e_1_3_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.104543"},{"key":"e_1_3_8_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/15284336.2019.1608714"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-019-0235-1"},{"key":"e_1_3_8_20_1","first-page":"642","article-title":"Update of the drug resistance mutations in HIV-1: June\/July 2014","volume":"22","author":"Wensing AM","year":"2014","unstructured":"Wensing AM, Calvez V, Gunthard HF, et\u00a0al. Update of the drug resistance mutations in HIV-1: June\/July 2014. Top Antivir Med 2014;22:642\u2013650.","journal-title":"Top Antivir Med"},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"e_1_3_8_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/48.5.699"},{"key":"e_1_3_8_23_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2019.0111"},{"key":"e_1_3_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30091-2"},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30092-4"},{"key":"e_1_3_8_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky467"},{"key":"e_1_3_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33095-7"},{"key":"e_1_3_8_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix1131"},{"key":"e_1_3_8_29_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3166"},{"key":"e_1_3_8_30_1","first-page":"1163","article-title":"Treatment simplification to atazanavir\/ritonavir\u2009+\u2009lamivudine versus maintenance of atazanavir\/ritonavir\u2009+\u2009two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomised trial (ATLAS-M)","volume":"72","author":"Di Giambenedetto S","year":"2017","unstructured":"Di Giambenedetto S, Fabbiani M, Quiros Roldan E, et\u00a0al. Treatment simplification to atazanavir\/ritonavir\u2009+\u2009lamivudine versus maintenance of atazanavir\/ritonavir\u2009+\u2009two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomised trial (ATLAS-M). J Antimicrob Chemother. 2017;72:1163\u20131171.","journal-title":"J Antimicrob Chemother."},{"key":"e_1_3_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00097-3"},{"key":"e_1_3_8_32_1","volume-title":"Poster PE3\/20 presented at: 17th European AIDS Conference","author":"Lathouwers E","year":"2019","unstructured":"Lathouwers E, Murrow S, Baugh B, et\u00a0al. Prevalence of archived HIV-1 DNA resistance-associated mutations and their lack of effect on virologic outcome at Week 96 in antiretroviral treatment-experienced, virologically suppressed patients receiving the once-daily, single-tablet regimen darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide (D\/C\/F\/TAF) in the EMERALD Phase III Trial. Poster PE3\/20 presented at: 17th European AIDS Conference; November 6\u20139, 2019; Basel, Switzerland."},{"key":"e_1_3_8_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000940"},{"key":"e_1_3_8_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000911"},{"key":"e_1_3_8_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318289545c"},{"key":"e_1_3_8_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318286415c"},{"key":"e_1_3_8_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000790"},{"key":"e_1_3_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30080-3"},{"key":"e_1_3_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30077-3"},{"key":"e_1_3_8_40_1","volume-title":"Abstract and oral presentation LB1 presented at: IDWeek","author":"Orkin C","year":"2018","unstructured":"Orkin C, Squires K, Molina J-M, et\u00a0al. Doravirine\/lamivudine\/tenofovir DF continues to be non-inferior to efavirenz\/emtricitabine\/tenofovir DF in treatment-na\u00efve adults with HIV-1 infection: week 96 results of the DRIVE-AHEAD Trial. Abstract and oral presentation LB1 presented at: IDWeek; October 3\u20137, 2018; San Francisco, CA, USA."},{"key":"e_1_3_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30336-4"},{"key":"e_1_3_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30149-3"},{"key":"e_1_3_8_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy505"},{"key":"e_1_3_8_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-6405-11-39"},{"key":"e_1_3_8_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000618"},{"key":"e_1_3_8_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834b4d48"},{"key":"e_1_3_8_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit122"},{"key":"e_1_3_8_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001344"},{"key":"e_1_3_8_49_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2017.0203"},{"key":"e_1_3_8_50_1","volume-title":"Abstract and poster MOPEB0289 presented at IAS Conference on HIV Science 2017","author":"Rockstroh J","year":"2017","unstructured":"Rockstroh J, Yazdanpanah Y, Di Perri G, et\u00a0al. Switching from TDF to TAF improves bone and renal safety independent of age, sex, race, or 3rd agent: Results from pooled analysis (N\u2009=\u20093816) of virologically suppressed HIV-1 infected adults. Abstract and poster MOPEB0289 presented at IAS Conference on HIV Science 2017; July 23\u201326, 2017; Paris, France."},{"key":"e_1_3_8_51_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222650"},{"key":"e_1_3_8_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32462-0"},{"key":"e_1_3_8_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002275"},{"key":"e_1_3_8_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31815ac499"},{"key":"e_1_3_8_55_1","doi-asserted-by":"publisher","DOI":"10.1310\/hct1206-313"},{"key":"e_1_3_8_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2012.00991.x"},{"key":"e_1_3_8_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit595"},{"key":"e_1_3_8_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0027-9684(15)30179-6"},{"key":"e_1_3_8_59_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz022"},{"key":"e_1_3_8_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1213"},{"key":"e_1_3_8_61_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1084"}],"container-title":["HIV Research & Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/25787489.2020.1844520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T15:01:12Z","timestamp":1717599672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/25787489.2020.1844520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1080\/25787489.2020.1844520"],"URL":"https:\/\/doi.org\/10.1080\/25787489.2020.1844520","relation":{},"ISSN":["2578-7489","2578-7470"],"issn-type":[{"type":"print","value":"2578-7489"},{"type":"electronic","value":"2578-7470"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=yhct21","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=yhct21","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-04-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}